|   From the Trenches

A Decade of Discovery

It is with great excitement that we at Nimbus are ringing in our 10th birthday this month. It’s been a momentous decade of ups and downs, many of them chronicled in dozens of posts here on LifeSciVC. At 10 years and still going, we’re proud to have reached a milestone that only about 10% of startups achieve.

This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   LifeSciVC

An Encyclopedia Of Advice For Startup Boards

By Bruce Booth, DPhil, Partner

Startups management teams often have a love-hate relationship with their Board of Directors: while Boards can be hugely helpful and constructive in the best of times, they can be dysfunctional and damaging in the worst. And most CEOs enjoy complaining about their Boards, even if just for entertaining effect on conference panels and the like.

Read more.


  |   From the Trenches

Maybe It’s Innate

Recently I read the article What’s Wrong With Me? that I saw re-posted on Twitter.  It’s a 2013 New Yorker article chronicling one woman’s journey through years of multi-symptom autoimmune/autoinflammatory disease with undiagnosed and untreated maladies.  It’s a long read, but one that I could not leave unfinished as I thought about my multiple friends who followed similar paths for years, each trying to understand what caused her symptoms.  Amongst my close friends are one with multiple sclerosis, one with ulcerative colitis, one with lupus and two with rheumatoid arthritis (RA).  Their diseases are given these titles that imply crisp definitions, but these are heterogenous diseases with overlapping symptoms, so they are difficult to diagnose and treat.  I’ll come back to what we might do to change that.

This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Why Reputation Is More Important Than Ever For Biotech Companies … And What You Can Do About It

“It takes twenty years to build a reputation, and five minutes to ruin it,” Warren Buffett said, and added “If you think about that, you’ll do things differently.” In biotech, a strong reputation is difficult to build, is even harder to establish quickly, and can be easily tarnished. So, what’s the landscape and what should we do about it?

This blog was co-written by Deanna Petersen, Chief Business Officer of AVROBIO, and Paul Newman, head of Corporate Communications, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Wotton replaces Gilman as CEO of cell, gene therapy startup Obsidian

Obsidian Therapeutics has named Paul Wotton as CEO. The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics.

Read more.